HR
HRTX.US Heron Therapeuti
- Market cap
- USD 59.1M
- P/E
- -
- P/B
- 15.35x
- ROE
- -504.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is HRTX.US undervalued?
Graham numberThe Graham number of Heron Therapeuti cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Heron Therapeuti fundamental analysis
No fundamental analysis for Heron Therapeuti yet.
Heron Therapeuti stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Heron Therapeuti
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of…
Full company profileHeron Therapeuti financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Heron Therapeuti annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.28M | 30.8M | 77.5M | 146M | 88.6M | 86.3M | 108M | 127M | 144M | 155M | 144M |
| Gross Profit | 1.24M | 26.2M | 50.0M | 84.3M | 52.4M | 40.3M | 52.8M | 61.9M | 106M | 114M | 102M |
| Operating Income | -171M | -195M | -184M | -211M | -228M | -218M | -175M | -111M | -11.5M | -2.54M | -11.3M |
| EBITDA | -170M | -192M | -182M | -201M | -225M | -215M | -172M | -104M | -5.06M | -17.9M | -18.5M |
| Net Income | -173M | -197M | -179M | -205M | -224M | -218M | -135M | -111M | -13.6M | -20.2M | -24.8M |
| EPS | -4.57 | -3.65 | -2.44 | -2.50 | -2.47 | -2.21 | -1.23 | -0.80 | -0.09 | -0.12 | -0.13 |
| Balance Sheet | |||||||||||
| Total Assets | 67.5M | 234M | 462M | 513M | 354M | 306M | 251M | 223M | 233M | 256M | 230M |
| Total Liabilities | 88.7M | 103M | 92.0M | 109M | 117M | 228M | 237M | 256M | 267M | 242M | 226M |
| Shareholders' Equity | -21.3M | 131M | 370M | 404M | 236M | 77.6M | 13.6M | -34.0M | -33.7M | 14.3M | 4.92M |
| Cash & Short-term Investments | 51.1M | 172M | 332M | 391M | 208M | 158M | 84.9M | 80.4M | 59.3M | 46.6M | 23.4M |
| Total Debt | 52.9M | 28.7M | 4.57M | 19.8M | 24.6M | 159M | 157M | 180M | 178M | 141M | 132M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -134M | -170M | -192M | -125M | -185M | -203M | -147M | -58.8M | -22.5M | -27.6M | -6.06M |
| Capital Expenditure | 3.14M | 2.55M | 9.17M | 7.15M | 6.81M | 3.02M | 1.83M | 1.55M | 1.71M | 317K | 841K |
| Free Cash Flow | -137M | -173M | -201M | -132M | -192M | -206M | -149M | -60.3M | -24.2M | -27.9M | -6.90M |
| Ratios | |||||||||||
| ROE | - | -150.6% | -48.3% | -50.7% | -94.9% | -280.6% | -991.1% | - | - | -140.9% | -504.6% |
| ROA | -256.6% | -84.3% | -38.7% | -39.9% | -63.5% | -71.2% | -53.6% | -49.7% | -5.8% | -7.9% | -10.8% |
| Net Profit Margin | -13,537.4% | -641.9% | -230.8% | -140.3% | -253.2% | -252.1% | -124.9% | -87.0% | -9.4% | -13.0% | -17.3% |
| Debt to Equity | - | 0.22x | 0.01x | 0.05x | 0.10x | 2.06x | 11.60x | - | - | 9.81x | 26.80x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Heron Therapeuti dividends
Heron Therapeuti has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Jan 13, 2014.
Who owns Heron Therapeuti
- Insiders 2.11%
- Institutions 63.10%
- Public & others 34.80%
- Shares outstanding 190M
- Free float 147M
Top funds holding HRTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 5.47M | 2.88% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 3.60M | 1.90% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 1.32M | 0.70% | -18.79% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 929K | 0.49% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 858K | 0.45% | -6.22% | Sep 2026 |
| Fidelity Extended Market Index | 833K | 0.44% | +31.69% | Sep 2026 |
| Bridge Builder Small Cap Fund | 617K | 0.32% | +853.25% | Oct 2026 |
| iShares Russell 2000 Value ETF | 448K | 0.24% | 0.00% | Oct 2026 |
| iShares Micro-Cap ETF | 447K | 0.24% | 0.00% | Oct 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 370K | 0.19% | +1.92% | Oct 2026 |
| Jacob Innovation Investor | 357K | 0.19% | 0.00% | Jun 2026 |
| Vanguard Health Care ETF | 328K | 0.17% | +0.13% | Sep 2026 |
| Fidelity Total Market Index | 318K | 0.17% | 0.00% | Sep 2026 |
| Schwab Small Cap Index | 297K | 0.16% | -28.09% | Sep 2026 |
| Fidelity Series Total Market Index | 273K | 0.14% | 0.00% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 265K | 0.14% | 0.00% | Sep 2026 |
| Advice Capital Globale | 250K | 0.13% | 0.00% | Jul 2026 |
| Highland Global Allocation A | 233K | 0.12% | 0.00% | Sep 2026 |
| Jacob Discovery Fd Instl | 217K | 0.11% | 0.00% | Jun 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 214K | 0.11% | -5.90% | Oct 2026 |
Top institutions holding HRTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Rubric Capital Management LP | 30.0M | 15.82% | 0.00% | Jun 2026 |
| Clearline Capital LP | 11.4M | 5.99% | -6.96% | Jun 2026 |
| BlackRock Inc | 10.6M | 5.56% | +4.40% | Jun 2026 |
| Velan Capital Investment Management LP | 8.75M | 4.61% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 7.78M | 4.10% | -0.35% | Jun 2026 |
| Tejara Capital Ltd | 6.49M | 3.42% | -0.28% | Sep 2026 |
| TANG CAPITAL MANAGEMENT LLC | 6.25M | 3.29% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 4.27M | 2.25% | +6.51% | Jun 2026 |
| Millennium Management LLC | 4.07M | 2.14% | -46.66% | Jun 2026 |
| JW Asset Management, LLC | 3.75M | 1.98% | 0.00% | Jun 2026 |
| State Street Corp | 3.23M | 1.70% | -16.00% | Jun 2026 |
| UBS Group AG | 3.00M | 1.58% | +31.11% | Jun 2026 |
| Pale Fire Capital SE | 2.51M | 1.32% | -7.54% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 2.35M | 1.24% | 0.00% | Jun 2026 |
| Richmond Brothers Inc | 1.79M | 0.94% | +24.75% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.58M | 0.83% | +20.71% | Jun 2026 |
| Renaissance Technologies Corp | 1.57M | 0.83% | +4.13% | Sep 2026 |
| AQR Capital Management LLC | 1.55M | 0.82% | +142.19% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 1.37M | 0.72% | +18.43% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.33M | 0.70% | +25.81% | Jun 2026 |
Heron Therapeuti company profile
- Company name
- Heron Therapeuti
- Ticker
- HRTX.US
- Exchange
- USA Stocks
- Listed since
- Aug 26, 1987
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 128
- Fiscal year end
- December
- Address
- 25 Fenton Main Street, Cary, NC, United States, 27511
- Phone
- 858 251 4400
- Website
- herontx.com
About Heron Therapeuti
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
Heron Therapeuti management
10- Mr. Craig Alexander CollardCEO & Director · born 1966
- Ms. Ira DuarteExecutive VP & CFO · born 1969
- Mr. Mark E. HensleyExecutive VP & COO · born 1983
- Dr. William P. Forbes Pharm. D., Pharm.D.Executive VP & Chief Development Officer · born 1962
- Melissa JarelVice President of Legal
- Mr. Ryan CraigVice President of Marketing
- Mr. John AikenExecutive Director of People Management & Training
- Dr. John C. Arthur Ph.D.Senior Vice President of Manufacturing Development · born 1966
- Mr. Robert SullivanChief Commercial Officer · born 1978
- Mr. Brett FleshmanChief Business Officer